Uncategorized

Novaliq’s NovaTears® Treatment for Evaporative Dry Eye Disease Launches in New Zealand and Receives Registrational Approval in Australia

by Business Wire • 2017/10/30 • 0 Comments

HEIDELBERG, Germany--(BUSINESS WIRE)--#MGD--Novaliq GmbH today announced the launch of NovaTears® in New Zealand and registrational approval in Australia.

Full Story →

← Ophthotech Corporation to Report Third Quarter 2017 Financial Results and Host Conference Call on Wednesday, November 8, 2017

Genotyping lacks support for guiding antioxidant treatment of AMD →

Post navigation